Aisling Capital Overview

  • Investor Type
  • Venture Capital

  • Status
  • Active

  • Professionals
  • 9

Professionals
  • Investments
  • 231

  • Portfolio
  • 19

  • Exits
  • 147

Exits

Aisling Capital General Information

Description

Founded in 2000, Aisling Capital is a venture capital firm based in New York, New York. The firm prefers to invest in seed-stage, early-stage, and growth-stage companies. The firm seeks to invest in the healthcare, and life sciences sectors in Mid Atlantic, South, and West Coasts.

Contact Information

Formerly Known As
Perseus Soros Management
Year Founded
2000
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
PE/Buyout
Primary Office
  • 888 Seventh Avenue
  • 12th Floor
  • New York, NY 10106
  • United States
+1 (212) 000-0000

Aisling Capital Investments & Acquisitions (231)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Treeline Biosciences 11-Oct-2022 Early Stage VC 00000 Drug Discovery Startup
00000 000000000 12-Sep-2022 00000 00000 0000 Drug Discovery Generating Revenue 000000 000000 00
0000 000 14-Jun-2022 00000 00000 000.00 Drug Discovery Pre-Clinical Trials 000000 000000 00
000000 00000000000 03-Nov-2021 00000 00000 0000 Drug Discovery Clinical Trials - Phase 2
000000 00000000000 07-Sep-2021 00000 00000 0000 Drug Discovery Generating Revenue 0000 000000 00
0000000 000000000 15-Jul-2021 00 000000000 Media and Information Services (B2B) Profitable
00000 09-Jul-2021 00000 00000 00000 Drug Discovery Clinical Trials - Phase 1 000000 0000000
0000000 01-Jul-2021 0000000000 Other Healthcare Services Profitable 000000 0000
Antios Therapeutics 09-Apr-2021 Early Stage VC 0000 Drug Discovery Clinical Trials - Phase 2
Treeline Biosciences 09-Apr-2021 Early Stage VC 00000 Drug Discovery Startup
You’re viewing 10 of 231 investments and acquisitions. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aisling Capital Exits (147)

Company Name Exit Date Exit Type Exit Size
Medical Knowledge Group 01-Feb-2022 Buyout/LBO 00.000
000000000 00000000 25-Jun-2021 000 00000
00000 0000 0000000 24-Jun-2021 000 00000
0000000 0000000000 07-May-2021 000 00000
0000 000000000 16-Apr-2021 000000000 00000000
000000 000000 16-Apr-2021 000 00000
00000 09-Apr-2021 000 000.00
00000000 000 10-Feb-2021 0000000 000000 00000
Aimmune Therapeutics 13-Oct-2020 Merger/Acquisition 00.00
Spruce Biosciences 09-Oct-2020 IPO 0000
You’re viewing 10 of 147 exits. Get the full list »

Aisling Capital Fund Performance

Fund Name Vintage Size Dry Powder DPI RVPI TVPI IRR

This information is available in the PitchBook Platform. To explore Aisling Capital‘s full profile, request access.

Request a free trial

Aisling Capital Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Aisling Capital Team (35)

Name Title Deals Funds Boards Office
Robert Wenzel Chief Financial Officer & Chief Compliance Officer, Legal New York, NY
Andrew Schiff MD Managing Partner 00 0 0 New York, NY
Steven Elms Managing Partner 00 0 0 New York, NY
Eric Aguiar MD Partner 00 0 0 New York, NY
Sunny Reddy Principal New York, NY
You’re viewing 5 of 35 team members. Get the full list »

Aisling Capital Co-Investors (110)

Name With Exits Lead Partner Series Industry
Cormorant Asset Management 6 0 Series chart Industry bar
Boxer Capital 0 0 Series chart Industry bar
Fidelity Management & Research 0 0 Series chart Industry bar
Abingworth 0 0 Series chart Industry bar
Citadel Enterprise Americas 0 Series chart Industry bar
You’re viewing 5 of 110 co-investors. Get the full list »